Mibefradil: a selective T-type calcium antagonist (Q41647645)

6 October 2017

1 reference

title

Mibefradil: a selective T-type calcium antagonist (English)

1 reference

6 October 2017

B M Massie

1

1 reference

6 October 2017

language of work or name

English

0 references

publication date

1 November 1997

1 reference

American Journal of Cardiology

6 October 2017

published in

1 reference

6 October 2017

volume

80

1 reference

6 October 2017

issue

9A

1 reference

6 October 2017

page(s)

23I-32I

1 reference

Effects of the new calcium antagonist mibefradil (Ro 40-5967) on exercise duration in patients with chronic stable angina pectoris: a multicenter, placebo-controlled study. Ro 40-5967 International Study Group.

6 October 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2897%2900791-1

Effects of a new calcium antagonist, mibefradil (Ro 40-5967), on silent ischemia in patients with stable chronic angina pectoris: a multicenter placebo-controlled study. The Mibefradil International Study Group.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2897%2900791-1

The design of the Mortality Assessment in Congestive Heart Failure Trial (MACH-1, mibefradil).

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2897%2900791-1

Increased survival after long-term treatment with mibefradil, a selective T-channel calcium antagonist, in heart failure

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2897%2900791-1

Pharmacologic and therapeutic differences among calcium channel antagonists: profile of mibefradil, a new calcium antagonist

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2897%2900791-1

The binding interactions of Ro 40-5967 at the L-type Ca2+ channel in cardiac tissue

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2897%2900791-1

The structurally novel Ca2+ channel blocker Ro 40-5967, which binds to the [3H] desmethoxyverapamil receptor, is devoid of the negative inotropic effects of verapamil in normal and failing rat hearts

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2897%2900791-1

Lack of Negative Inotropic Effects of the New Calcium Antagonist Ro 40–5967 in Patients with Stable Angina Pectoris

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2897%2900791-1

Dose-response characteristics of mibefradil, a novel calcium antagonist, in the treatment of essential hypertension

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2897%2900791-1

Selective inhibition of T-type Ca2+ channels by Ro 40-5967

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2897%2900791-1

Protein families that mediate Ca2+ signaling in the cardiovascular system

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2897%2900791-1

Physiologic and pathophysiologic relevance of T-type calcium-ion channels: potential indications for T-type calcium antagonists

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2897%2900791-1

T-type Ca2+ current is expressed in hypertrophied adult feline left ventricular myocytes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2897%2900791-1

Effects of Ro 40-5967, a novel calcium antagonist, on myocardial function during ischemia induced by lowering coronary perfusion pressure in dogs: comparison with verapamil

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2897%2900791-1

Potential-dependent inhibition of cardiac Ca2+ inward currents by Ro 40-5967 and verapamil: relation to negative inotropy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2897%2900791-1

Calcium channels, potassium channels, and voltage dependence of arterial smooth muscle tone

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2897%2900791-1

Hemodynamic and humoral effects of the novel calcium antagonist Ro 40-5967 in patients with hypertension

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2897%2900791-1

Mibefradil prevents neointima formation after vascular injury in rats. Possible role of the blockade of the T-type voltage-operated calcium channel

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2897%2900791-1

Effects of calcium channel blockade on the aortic intima in spontaneously hypertensive rats

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2897%2900791-1

A randomised, double-blind trial comparing mibefradil and amlodipine: two long-acting calcium antagonists with similar efficacy but different tolerability profiles. Mibefradil International Study Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2897%2900791-1

Antihypertensive effects of mibefradil: a double-blind comparison with diltiazem CD.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2897%2900791-1

The antihypertensive efficacy of the novel calcium antagonist mibefradil in comparison with nifedipine GITS in moderate to severe hypertensives with ambulatory hypertension

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2897%2900791-1

Efficacy of mibefradil compared with amlodipine in suppressing exercise-induced and daily silent ischemia: results of a multicenter, placebo-controlled trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2897%2900791-1

Long-term antianginal and antiischemic effects of mibefradil, the novel T-type calcium channel blocker: a multicenter, double-blind, placebo-controlled, randomized comparison with sustained-release diltiazem

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2897%2900791-1

10.1016/S0002-9149(97)00791-1

7 January 2021

Identifiers

DOI

1 reference

6 October 2017

1 reference